Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation

Michael Y. Shapira; Igor B. Resnick; Sunwen Chou; Avidan U. Neumann; Nell S. Lurain; Thomas Stamminger; Orit Caplan; Niveen Saleh; Thomas Efferth; Manfred Marschall; Dana G. Wolf

doi:10.1086/587106

Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation

Michael Y. Shapira, Igor B. Resnick, Sunwen Chou, Avidan U. Neumann, Nell S. Lurain, Thomas Stamminger, Orit Caplan, Niveen Saleh, Thomas Efferth, Manfred Marschall, Dana G. Wolf

The Mina and Everard Goodman Faculty of Life Sciences - at Bar-Ilan University

Research output: Contribution to journal › Article › peer-review

144 Scopus citations

Abstract

This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation. Artesunate treatment resulted in a 1.7-2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9-1.9 days, indicating a highly effective block in viral replication.

Original language	English
Pages (from-to)	1455-1457
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	46
Issue number	9
DOIs	https://doi.org/10.1086/587106
State	Published - 1 May 2008

Bibliographical note

Funding Information:
Financial support. Israeli Ministry of Science, Israel Science Foundation, and National Institutes of Health (AI39938). Potential conflict of interest. All authors: no conflicts

Funding

Financial support. Israeli Ministry of Science, Israel Science Foundation, and National Institutes of Health (AI39938). Potential conflict of interest. All authors: no conflicts

Funders	Funder number
Israeli Ministry of Science, Israel Science Foundation
National Institutes of Health
National Institute of Allergy and Infectious Diseases	R01AI039938

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1086/587106

Cite this

Shapira, M. Y., Resnick, I. B., Chou, S., Neumann, A. U., Lurain, N. S., Stamminger, T., Caplan, O., Saleh, N., Efferth, T., Marschall, M., & Wolf, D. G. (2008). Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clinical Infectious Diseases, 46(9), 1455-1457. https://doi.org/10.1086/587106

@article{9a8ff8194e4e43ff8aff6cae001f3f95,

title = "Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation",

abstract = "This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation. Artesunate treatment resulted in a 1.7-2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9-1.9 days, indicating a highly effective block in viral replication.",

author = "Shapira, {Michael Y.} and Resnick, {Igor B.} and Sunwen Chou and Neumann, {Avidan U.} and Lurain, {Nell S.} and Thomas Stamminger and Orit Caplan and Niveen Saleh and Thomas Efferth and Manfred Marschall and Wolf, {Dana G.}",

note = "Funding Information: Financial support. Israeli Ministry of Science, Israel Science Foundation, and National Institutes of Health (AI39938). Potential conflict of interest. All authors: no conflicts",

year = "2008",

month = may,

day = "1",

doi = "10.1086/587106",

language = "אנגלית",

volume = "46",

pages = "1455--1457",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "9",

}

Shapira, MY, Resnick, IB, Chou, S, Neumann, AU, Lurain, NS, Stamminger, T, Caplan, O, Saleh, N, Efferth, T, Marschall, M & Wolf, DG 2008, 'Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation', Clinical Infectious Diseases, vol. 46, no. 9, pp. 1455-1457. https://doi.org/10.1086/587106

TY - JOUR

T1 - Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation

AU - Shapira, Michael Y.

AU - Resnick, Igor B.

AU - Chou, Sunwen

AU - Neumann, Avidan U.

AU - Lurain, Nell S.

AU - Stamminger, Thomas

AU - Caplan, Orit

AU - Saleh, Niveen

AU - Efferth, Thomas

AU - Marschall, Manfred

AU - Wolf, Dana G.

N1 - Funding Information: Financial support. Israeli Ministry of Science, Israel Science Foundation, and National Institutes of Health (AI39938). Potential conflict of interest. All authors: no conflicts

PY - 2008/5/1

Y1 - 2008/5/1

N2 - This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation. Artesunate treatment resulted in a 1.7-2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9-1.9 days, indicating a highly effective block in viral replication.

AB - This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation. Artesunate treatment resulted in a 1.7-2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9-1.9 days, indicating a highly effective block in viral replication.

UR - http://www.scopus.com/inward/record.url?scp=42549168601&partnerID=8YFLogxK

U2 - 10.1086/587106

DO - 10.1086/587106

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 18419454

AN - SCOPUS:42549168601

SN - 1058-4838

VL - 46

SP - 1455

EP - 1457

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 9

ER -

Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation

Abstract

Bibliographical note

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this